This study describes the identification of an antibiotic class acting via LpxH, involved in lipopolysaccharide synthesis having potent in vivo efficacy against bloodstream infections caused by the critical Gram-negative pathogens E. coli and Klebsiella pneumoniae. Further development of this class of antibiotics could make an important contribution to the ongoing struggle against antibiotic resistance.
https://www.pnas.org/doi/10.1073/pnas.2317274121 (open access)
More antibiotics is not the solution. We need to be moving away from antibiotics, and drastically decreasing their use/overuse.
Goodluck with that.